Background
The approval of long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) heightened the urgency of ensuring effective implementation. Our study assesses readiness and barriers to implement LAI CAB/RPV across Ryan White-funded clinics in the U.S.
Methods
We conducted a cross-sectional survey between December 2020 and January 2021 using validated four-item measures: Acceptability (AIM), Appropriateness (IAM), and Feasibility (FIM) of intervention measures Associations between measures and clinic characteristics were evaluated using Spearman rank correlations. A 5-point Likert scale ranked potential barriers of implementation responses. Open-ended questions were analyzed using a deductive thematic approach.
Results
Forty-four out of 270 (16%) clinics completed the survey (38% federally qualified health centers, 36% academic, 20% community-based organizations (CBO), 14% hospital outpatient and 9% non-profit clinics). Means, standard deviation, and ranges were AIM (17.6 (2.4) [12-20]); IAM (17.6 (2.4) [13-20]), and FIM (16.8 (2.9) [7-20]). Twenty percent were not at all and 52% were slightly or somewhat ready to implement LAI CAB/RPV. There was significant association between AIM and proportion of Medicaid patients (AIM, rho = 0.312, p= 0.050). CBOs scored the highest readiness measures (AIM mean = 19.50, SD = (1.41); IAM mean = 19.25, SD = 1.49, FIM mean 19.13, SD (1.36) compared to other clinics. Implementation barriers were cost and patients’ nonadherence to visits leading to drug resistance.
Conclusion
There is variability of readiness, yet high levels of perceived acceptability and appropriateness of implementing LAI CAB/RPV among Ryan White clinics, necessitating tailored interventions for successful implementation. Special focus on addressing the barriers of adherence and cost of implementation is needed.